First-Line Treatment of Hairy Cell Leukemia with Cladribine Followed by Rituximab Consolidation Significantly Improves Leukemia-Free Survival
Authors:
- 1 August 2021
- journal article
- editorial
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 21 (8) , 564-566
Abstract
No abstract availableFunding Information
- American University of Beirut
This publication has 8 references indexed in Scilit:
- Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell LeukemiaJournal of Clinical Oncology, 2020
- Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatmentAmerican Journal of Hematology, 2019
- Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemiaBlood, 2017
- How I manage patients with hairy cell leukaemiaBritish Journal of Haematology, 2017
- Long‐term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trialBritish Journal of Haematology, 2016
- BRAFMutations in Hairy-Cell LeukemiaNew England Journal of Medicine, 2011
- Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosisBritish Journal of Haematology, 2009
- Extended Follow-Up of Patients With Hairy Cell Leukemia After Treatment With CladribineJournal of Clinical Oncology, 2003